Table 1.

Patient characteristics

Characteristics		n (%)
Age, y Gender RT BED, Gy Types HBsAg Child Pugh classification PS (ECOG) Concomitant disease Target therapy Center location Diameter, cm AFP, ng/L PLT, 109/L HGB, g/L TBIL, μmol/L Albumin, g/L ALT, U/L AST, U/L	≥54/<54 Male/Female A-RT/2D-RT/Non-RT ≥58.9 /<58.9/0 I /II/III/IV Negative/Positive A/B 0–1/2–3 Yes/No Yes/No Right/Left ≥5/<5 ≤20/20 ~ 400/≥400 ≥100/<100 ≥120/<120 ≥20/<20 ≥35/<35 ≥50/<50 ≥50/<50	41(51.2)/39(48.8) 75(93.7)/5(6.3) 54(67.5)/10(12.5)/16(20.0) 42(52.5)/22(27.5)/16(20.0) 12(15.0)/28(35.0)/18(22.5)/22(27.5) 23(28.7)/57(71.3) 50(62.5)/30(37.5) 59(73.8)/21(26.2) 62(77.5)/18(22.5) 30(37.5)/50(62.5) 60(75.0)/20(25.0) 56(70.0)/24(30.0) 13(16.3)/23(28.7)/44(55.0) 54(67.5)/26(32.5) 51(63.7)/29(36.3) 34(37.5)/46(57.5) 30(37.5)/50(62.5) 30(37.5)/50(62.5) 46(57.5)/34(42.5)

RT radiotherapy, A-RT accurate radiotherapy, 2D-RT two-dimensional radiotherapy, Non-RT non-radiotherapy, BED biologically effective dose, Types types of tumor thrombi, HBsAg hepatitis B surface antigen, PS performance status, ECOG Eastern Cooperative Oncology Group; Concomitant disease include hepatitis and hepatocirrhosis; Targeted therapy: sorafenib; AFP alpha–fetoprotein, PLT platelet, HGB Hemoglobin, TBIL total bilirubin, ALT alanine aminotransferase, AST aspartate aminotransferase